TheraRadar
Data updated: May 26, 2026

EPSOLAY (benzoyl peroxide)

Trial Activity: Mature
Dermatology Approved 2022-04-22

Epsolay is used for adults who have inflammatory lesions associated with rosacea. This medication helps patients with the specific skin bumps and blemishes that occur with this condition. It is prescribed to manage these inflammatory symptoms in the adult population.

Source: FDA Label • MAYNE PHARMA

How EPSOLAY Works

This medication works by acting as an oxidizing agent that provides both bactericidal and keratolytic effects on the skin. While the exact way it improves rosacea is not fully understood, these properties help address the underlying skin issues.

Source: FDA Label

Development Insights

University of Oklahoma conducting 1 trials (33%)
4 indications explored (Focused)
molluscum contagiosum (1 trials)
acne (1 trials)
healthy (1 trials)
1
Indication
--
Phase 3 Trials
4
Years on Market

Details

Status
Prescription
First Approved
2022-04-22
Patent Cliff
2041

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: BENZOYL PEROXIDE

EPSOLAY Approval History

2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2022 to 2022
Apr 2022 ORIGINAL
Update

What EPSOLAY Treats

1 indications

EPSOLAY is approved for 1 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Rosacea
Source: FDA Label

EPSOLAY Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to EPSOLAY

3 of 12

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CLOBEX
CLOBETASOL PROPIONATE
1 shared
GALDERMA LABS LP
Shared indications:
EMROSI
MINOCYCLINE HYDROCHLORIDE
1 shared
JOURNEY
Shared indications:
FINACEA
AZELAIC ACID
1 shared
LEO PHARMA AS
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT05536882 IRB# 14663 Ph 3 withdrawn MC RCT - BPO vs Adapalene
NCT04548349 results posted 2020P000595 Ph 4 completed Profiling the Skin Microbiome in Response to Altreno in Acne Patients
NCT02589405 Benzac results posted RD.03.SPR.105041 Ph 4 completed Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EPSOLAY FDA Label Details

Indications & Usage

EPSOLAY is indicated for the treatment of Rosacea.

View full patent landscape →
14 OB patents · 5 families · 114 international docs across 15 countries

EPSOLAY Patents & Exclusivity

Latest Patent: May 2041

Patents (14 active)

US12257348 Expires May 23, 2041
US12295935 Expires Dec 27, 2040
US11628155 Expires Dec 27, 2040
US11426378 Expires Aug 18, 2040
US10945987 Expires Feb 19, 2040
US11877997 Expires Feb 19, 2040
US10933046 Expires Feb 19, 2040
US11541026 Expires Feb 19, 2040
US11986456 Expires Feb 19, 2040
US11865100 Expires Feb 19, 2040
US9687465 Expires Nov 27, 2032
US9868103 Expires Aug 8, 2028
US12350382 Expires Feb 3, 2028
US12156946 Expires Feb 3, 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for EPSOLAY

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2041
  • 14 active patents

Trial Analysis

  • 3 total trials
  • Stage: Mature

Competitive Landscape

  • 12 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment